Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: EVMN 2 – 3 OVID (1 Tie) Matrix Metrics: EVMN 2 – 7 OVID

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVMN carries a Unified Composite Score of 30.1/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas OVID carries 45.7/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. EVMN 30.1/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs OVID
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.1 / 100 SELL
Tech 5.0 Fund 35.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.40
-5.51% 1D
Market Cap $479.4M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 0.98β · 97% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $2.52 · SMA50: $2.50

6-Pillar Scorecard Institutional Category Breakdown (EVMN 2 – 3 OVID)

Columns: Metric · EVMN · OVID
1. Valuation Multiples OVID
Forward P/E N/M 1.8x
Trailing P/E N/M 1.8x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OVID
Revenue Growth (YoY) +0.0% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.5M
Market Cap $315.5M $479.4M
3. Profitability & Quality OVID
Gross Margin N/A 100.0%
Operating Margin 0.0% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.5% -35.4%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 209.0% (53rd %ile) 131.0% (30th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (2) vs OVID (7)
Institutional Metric EVMN OVID Criterion Row Edge
Market Capitalization
Scale
$315.5M $479.4M Larger Scale OVID
Trailing P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
+0.0% -88.3% Higher Growth EVMN
Operating Margin (TTM)
Profitability
0.0% -4693.7% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.5% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
8% ($5–$33) 63% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 0.98β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
30.1 / 100 (SELL) 45.7 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +25.7 pp
EVMN: +37.33% · OVID: +11.63%
3M Horizon OVID +34.58 pp
EVMN: -50.07% · OVID: -15.49%
6M Horizon OVID +67.16 pp
EVMN: -67.57% · OVID: -0.41%
1Y Horizon OVID +161.03 pp
EVMN: -61.03% · OVID: +100.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVMN Revenue OVID Revenue EVMN Op. Margin OVID Op. Margin Margin Leader
FY2020 N/A $10M N/A -645.4% OVID
FY2021 N/A $210M N/A 59.6% OVID
FY2022 N/A $0M N/A -3696.4% OVID
FY2023 N/A $0M N/A -15122.7% OVID
FY2024 $10M $0M -1000.2% -10933.7% EVMN
FY2025 $10M $10M -623.6% -585.2% OVID

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID CONSOLIDATION
150d in phase · OBV NEUTRAL
Current IV 131.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $479.4M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs OVID Key Questions & Quantitative Answers

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVMN carries a Unified Composite Score of 30.1/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas OVID carries 45.7/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. EVMN 30.1/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

OVID leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), EVMN cumulative revenue shifted +0.0% while OVID shifted +0.0%. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.